Patient | MSA subtype | Age at disease onset | Disease duration (y) | Levodopa naive dystonia | Initial levodopa response | Latency to introduction of levodopa (y) | Latency to levodopa induced dyskinesias (y) | Maximum levodopa dose (mg/day) | Site of dyskinesias | Time course of dyskinesias | Nature of dyskinesias |
---|---|---|---|---|---|---|---|---|---|---|---|
*Patients with MSA-P confirmed by postmortem. | |||||||||||
1 | MSA-P | 61 | 8 | Antecollis | Moderate | 1 | 3 | 600 | Cervical | Peak dose | Dystonic |
2* | MSA-P | 54 | 5 | Dystonic arm | Excellent | 1 | 4 | 500 | Generalised | Peak dose | Choreodystonic |
8 | MSA-P | 55 | 9 | None | Excellent | 2 | 3 | 500 | Craniocervical | Peak dose | Dystonic |
9 | MSA-P | 59 | 7 | Writers cramp | Good | 1 | 4 | 600 | Craniocervical | Peak dose | Dystonic |
10 | MSA-P | 64 | 5 | None | Good | 1 | 2 | 600 | Both legs | Peak dose, off period | Choreodystonic |
11 | MSA-P | 47 | 13 | Antecollis | Excellent | 3 | 1 | 750 | Craniocervical | Peak dose, off period | Dystonic |
12 | MSA-P | 74 | 5 | Antecollis | Moderate | 1 | 2 | 600 | Cervical | Peak dose | Dystonic |
13 | MSA-P | 54 | 6 | None | Good | 1 | 0.5 | 300 | Craniocervical | Peak dose | Dystonic |
14* | MSA-P | 57 | 4 | Dystonic foot posturing | Excellent | 1 | 1 | 600 | Left arm | End of dose | Dystonic |
15 | MSA-P | 61 | 7 | None | Good | 2 | 3 | 400 | Right leg | Peak dose | Choreatic |
16* | MSA-P | 47 | 4 | None | Moderate | 1 | 2 | 500 | Generalised | Peak dose | Dystonic |
18* | MSA-P | 55 | 5 | None | Moderate | 1 | 3 | 700 | Craniocervical | Peak dose | Dystonic |
n=12 | Mean 57.3 y | Mean 7.3 y | Mean 1.4 y | Mean 2.3 y | Mean 550 mg/day |